Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis for pre-seasonal therapy
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Epinastine (Primary)
- Indications Allergic conjunctivitis
- Focus Pharmacodynamics
- Sponsors Santen Pharmaceutical
- 07 May 2019 Status changed from active, no longer recruiting to completed.
- 16 Jan 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Jan 2018 New trial record